Mirae Asset Global Investments Co. Ltd. grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 21.7% during the third quarter, HoldingsChannel.com reports. The firm owned 104,527 shares of the medical research company’s stock after acquiring an additional 18,611 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Amgen were worth $21,711,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Amgen by 4.4% during the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after buying an additional 1,505,266 shares during the period. Natixis increased its stake in shares of Amgen by 2,612.1% during the second quarter. Natixis now owns 529,816 shares of the medical research company’s stock valued at $97,799,000 after buying an additional 510,281 shares during the period. Candriam Luxembourg S.C.A. increased its stake in shares of Amgen by 54.8% during the third quarter. Candriam Luxembourg S.C.A. now owns 1,075,050 shares of the medical research company’s stock valued at $222,847,000 after buying an additional 380,562 shares during the period. O Shaughnessy Asset Management LLC increased its stake in shares of Amgen by 404.6% during the third quarter. O Shaughnessy Asset Management LLC now owns 456,500 shares of the medical research company’s stock valued at $94,333,000 after buying an additional 366,027 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Amgen by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after buying an additional 343,690 shares during the period. Institutional investors and hedge funds own 76.94% of the company’s stock.
Shares of AMGN stock opened at $191.44 on Friday. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19. The stock has a market cap of $126.81 billion, a P/E ratio of 15.22, a P/E/G ratio of 2.07 and a beta of 1.41. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be issued a $1.45 dividend. This represents a $5.80 annualized dividend and a yield of 3.03%. This is an increase from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is currently 41.97%.
Several equities analysts have recently commented on AMGN shares. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Monday, October 1st. Mizuho restated a “buy” rating and set a $206.00 price target on shares of Amgen in a research note on Friday, October 26th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Amgen in a research note on Thursday, October 25th. Royal Bank of Canada cut their price target on Amgen to $182.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 31st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $223.00 price target on shares of Amgen in a research note on Tuesday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $205.68.
In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.19% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) Holdings Increased by Mirae Asset Global Investments Co. Ltd.” was reported by BBNS and is owned by of BBNS. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://baseballnewssource.com/2018/12/08/amgen-inc-amgn-holdings-increased-by-mirae-asset-global-investments-co-ltd/3064247.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: What are the reasons investors use put options?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.